Obicetrapib

Phase 3Small molecule

NNewAmsterdam Pharma

Obicetrapib is one of 159 small molecule programs targeting MPA. It is currently in Phase 3.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

MPARecruiting

Preclinical Alzheimer's DiseaseNot yet recruiting

ImagingRecruiting

MetabolismActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

ARTRecruiting

LipidemiaActive, not recruiting

MPAPhase 2

Recruiting

Preclinical Alzheimer's DiseasePhase 2

Not yet recruiting

ImagingPhase 3

Recruiting

MetabolismPhase 1

Active, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

ARTPhase 2

Recruiting

LipidemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Intropin

Lescol

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Approved

—4

Welchol

CCosette Pharmaceuticals, Inc.

Approved

—5

Nimotop

AAzurity Pharmaceuticals

Colcrys

1 7

Pelacarsen

Novartis

Phase 3

1 8

Cagrilintide

Novo Nordisk

Phase 3

1 9

Obicetrapib

NNewAmsterdam Pharma

Phase 3

1 10

Berberine

XXijing Hospital of Digestive Diseases

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cardiovascular Disease

NCT05202509

Phase 2Recruiting

ART

NCT06982508

Q1 2027

Phase 3Recruiting

Imaging

NCT06305559

Q2 2028

Phase 3Active, not recruiting

Lipidemia

NCT07219602

Q2 2029

Phase 2Not yet recruiting

Preclinical Alzheimer's Disease

NCT07794670

Clinical

Trials by Indication[1]

Randomized3 trials

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Completed·NNewAmsterdam Pharma·Phase 3·NCT05142722·2,530 enrolled

Randomized Study of Obicetrapib in Combination With Ezetimibe

Completed·NNewAmsterdam Pharma·Phase 2·NCT04770389·112 enrolled

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Completed·NNewAmsterdam Pharma·Phase 2·NCT04753606·120 enrolled

Lip1 trial

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Completed·NNewAmsterdam Pharma·Phase 3·NCT05425745·354 enrolled

Atorvastatin1 trial

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

Completed·NNewAmsterdam Pharma·Phase 1·NCT06081166·74 enrolled

Statin1 trial

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Completed·NNewAmsterdam Pharma·Phase 2·NCT05421078·102 enrolled

Early Alzheimer's Disease1 trial

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Completed·NNewAmsterdam Pharma·Phase 2·NCT05161715·13 enrolled

11 more indications

ART1 trial

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Recruiting·NNewAmsterdam Pharma·Phase 2·NCT06982508·100 enrolled

Drug Interactions1 trial

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

Completed·NNewAmsterdam Pharma·Phase 1·NCT06547359·94 enrolled

Cardiovascular Disease1 trial

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting·NNewAmsterdam Pharma·Phase 3·NCT05202509·9,541 enrolled

Metabolism1 trial

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Active, not recruiting·NNewAmsterdam Pharma·Phase 1·NCT05972278·22 enrolled

Oral1 trial

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Completed·NNewAmsterdam Pharma·Phase 1·NCT06250205·30 enrolled

Moderate Hepatic Impairment1 trial

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Completed·NNewAmsterdam Pharma·Phase 1·NCT06048302·18 enrolled

MPA1 trial

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Recruiting·NNewAmsterdam Pharma·Phase 2·NCT06496243·69 enrolled

Imaging1 trial

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Recruiting·NNewAmsterdam Pharma·Phase 3·NCT06305559·300 enrolled

Lipidemia1 trial

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)

Active, not recruiting·NNewAmsterdam Pharma·Phase 3·NCT07219602·300 enrolled

Preclinical Alzheimer's Disease1 trial

A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)

Not yet recruiting·NNewAmsterdam Pharma·Phase 2·NCT07794670·400 enrolled

Unspecified1 trial

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Completed·NNewAmsterdam Pharma·Phase 2·NCT05266586·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Obicetrapib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Obicetrapib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Obicetrapib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NewAmsterdam Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNewAmsterdam Pharma

Obicetrapib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2028

Q2 2029

Trials by Indication[1]

Randomized3 trials

Lip1 trial

Atorvastatin1 trial

Statin1 trial

Early Alzheimer's Disease1 trial

ART1 trial

Drug Interactions1 trial

Cardiovascular Disease1 trial

Metabolism1 trial

Oral1 trial

Moderate Hepatic Impairment1 trial

MPA1 trial

Imaging1 trial

Lipidemia1 trial

Preclinical Alzheimer's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News